Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The market for weight loss drugs is white-hot, and competition is heating up fast. This Danish company is already facing a ...

Misperceptions and a focus on weight-loss medications risk oversimplifying a complex health crisis. Read more at straitstimes ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Viking is developing what might be a game-changing medication in the segment.

CVS drops Lilly's Zepbound for Novo's Wegovy in rebate-driven dealTelehealth partnerships expand access with cheaper ...

Danish drugmaker Novo Nordisk (NOV: N) has secured a significant advantage in the high-stakes obesity drug market after ...